FELIQS announces $9 Million Series A Financing to Advance FLQ-101 Clinical Program for Retinopathy of Prematurity

FUKUOKA, Japan & NEW YORK--(BUSINESS WIRE)--FELIQS Corporation (“FELIQS”), a biotechnology company developing first-in-class small molecule therapeutics targeting oxidized lipids for rare pediatric retinal diseases, today announced the successful completion of a $9 million Series A funding round, co-led by a major American pharmaceutical company and Beyond Next Ventures Inc., with additional participation from, Japan Science and Technology Agency and existing investors, Mitsubishi UFJ Capital C